From One Month To One Year Post-launch, The User-base Of Roche/Genentech/Chugai's Perjeta Has More Than Doubled

           From One Month To One Year Post-launch, The User-base Of
            Roche/Genentech/Chugai's Perjeta Has More Than Doubled

Moreover, the Majority of Oncologists Who Have Not Yet Prescribed Perjeta
Intend to Do So in the Next Three Months, According to a New Report from
BioTrends Research Group

PR Newswire

EXTON, Pa., Aug. 13, 2013

EXTON, Pa., Aug. 13, 2013 /PRNewswire/ -- BioTrends Research Group, one of the
world's leading research and advisory firms for specialized biopharmaceutical
issues, finds that, one year post-launch, the user-base of
Roche/Genentech/Chugai's Perjeta has more than doubled since BioTrends first
assessed physician uptake one month post-launch. According to LaunchTrends®:
Perjeta and Kadcyla (US), after approximately one year on the market, 77
percent of surveyed U.S. oncologists have prescribed Perjeta (pertuzumab) in
an average of six of their HER2-overexpressing (HER2+) breast cancer patients.
However, of those physicians who have not already prescribed Perjeta, 76
percent intend to do so in the next three months. Approximately five percent
of surveyed oncologists do not plan on prescribing Perjeta in the future.

The report also focuses on uptake of Roche/Genentech/Chugai's Kadcyla
(ado-trastuzumab emtansine); approximately four months after launch, almost
two-thirds of surveyed oncologists have now prescribed Kadcyla in an average
of seven of their HER2+ patients. Of non-prescribers, 97 percent plan on
prescribing Kadcyla in the next year.

"Based on the study data, Perjeta and Kadcyla treatment rates are anticipated
to increase considerably in the next year," said Decision Resources Group
Principal Analyst Amy Duval, M.Res. "This will likely translate into a
substantial increase in both the user- and patient-base for both treatment
options."

The recently published report also finds that more than 90 percent of current
Perjeta and Kadcyla users are moderately-to-highly satisfied with the
products, typically  citing that their high satisfaction is attributed to
patients having an initial positive response to treatment, in addition to good
tolerability profiles of the drugs.

LaunchTrends: Perjeta and Kadcyla (US) is a four-wave syndicated report series
designed to track the uptake of Perjeta at one month, three months, six
months, one year and one year and nine months after the launch of Perjeta, and
four months and one year following Kadcyla's commercial availability based
upon primary research with U.S. oncologists. LaunchTrends assess trial and use
of new products, obstacles to use, reasons to use, typical patient types, line
of therapy, product perceptions, promotional efforts/messages and product
satisfaction. In the current wave of research, BioTrends surveyed 74 U.S.
oncologists in June 2013 and conducted qualitative interviews with a subset of
15 of the respondents in June 2013.

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please visit www.bio-trends.com. BioTrends is a
Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group
atwww.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks of their respective holders.

For more information, contact:
Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com

SOURCE BioTrends Research Group

Website: http://www.bio-trends.com
 
Press spacebar to pause and continue. Press esc to stop.